Cargando…

Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens

Direct-acting antivirals (DAA) regimens have provided hope for eliminating hepatitis C virus (HCV) infection. Patients following ineffective therapy with DAA, especially those previously treated with inhibitors of non-structural protein 5A (NS5A), remain a challenge. The study aimed to assess the ef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tronina, Olga, Brzdęk, Michał, Zarębska-Michaluk, Dorota, Dybowska, Dorota, Lorenc, Beata, Janczewska, Ewa, Mazur, Włodzimierz, Parfieniuk-Kowerda, Anna, Piekarska, Anna, Krygier, Rafał, Klapaczyński, Jakub, Berak, Hanna, Jaroszewicz, Jerzy, Garlicki, Aleksander, Tomasiewicz, Krzysztof, Citko, Jolanta, Flisiak, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10055110/ https://www.ncbi.nlm.nih.gov/pubmed/36992388 http://dx.doi.org/10.3390/v15030677

Ejemplares similares

Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Pangenotypic triple versus double therapy in HCV-infected patients after prior failure of direct-acting antivirals
por: Flisiak, Robert, et al.
Publicado: (2023)

Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2021)

Real-World Effectiveness and Safety of Direct-Acting Antivirals in Patients with Chronic Hepatitis C and Epilepsy: An Epi-Ter-2 Study in Poland
por: Pazgan-Simon, Monika, et al.
Publicado: (2023)

Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era
por: Brzdęk, Michał, et al.
Publicado: (2023)

Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders
por: Dybowska, Dorota, et al.
Publicado: (2023)

Real-world direct-acting antiviral treatment in kidney transplant and hemodialysis patients: the EpiTer-2 multicenter observational study
por: Tronina, Olga, et al.
Publicado: (2021)

Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-week regimen in a real-world setting
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2019)

HCV Genotype Has No Influence on the Incidence of Diabetes—EpiTer Multicentre Study
por: Rajewski, Paweł, et al.
Publicado: (2022)

Five-Year Follow-Up of Cured HCV Patients under Real-World Interferon-Free Therapy
por: Flisiak, Robert, et al.
Publicado: (2021)

Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study
por: Janczewska, Ewa, et al.
Publicado: (2021)

Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2023
por: Tomasiewicz, Krzysztof, et al.
Publicado: (2023)

The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study
por: Janczewska, Ewa, et al.
Publicado: (2018)

Searching for the optimal population for hepatitis C virus screening in Poland
por: Piekarska, Anna, et al.
Publicado: (2020)

Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study
por: Rajewski, Paweł, et al.
Publicado: (2022)

Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2019)

Perspectives of hepatitis C virus (HCV) elimination in Poland
por: Flisiak, Robert, et al.
Publicado: (2019)

Immune regulation and viral diversity as correlates of natural and treatment induced immune control in persistent hepatitis B virus (HBV) infection
por: Parfieniuk-Kowerda, Anna, et al.
Publicado: (2015)

Prevalence of HCV genotypes in Poland – the EpiTer study
por: Flisiak, Robert, et al.
Publicado: (2016)

Efficacy of HCV treatment in Poland at the turn of the interferon era – the EpiTer study
por: Flisiak, Robert, et al.
Publicado: (2016)

COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Global Elimination of HCV—Why Is Poland Still So Far from the Goal?
por: Tronina, Olga, et al.
Publicado: (2023)

Effect of comedication on ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin therapy in chronic hepatitis C – a real-world study
por: Simon, Krzysztof Adam, et al.
Publicado: (2019)

Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C
por: Brzdęk, Michał, et al.
Publicado: (2023)

Remdesivir Decreases Mortality in COVID-19 Patients with Active Malignancy
por: Jaroszewicz, Jerzy, et al.
Publicado: (2022)

The Course of COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases
por: Rorat, Marta, et al.
Publicado: (2022)

The occurrence of autoantibodies in patients with chronic HCV infection, including patients dialyzed and after kidney transplantation
por: Łapiński, Tadeusz W., et al.
Publicado: (2016)

The interplay between Th17 and T-regulatory responses as well as adipokines in the progression of non-alcoholic fatty liver disease
por: Świderska, Magdalena, et al.
Publicado: (2017)

Chronic hepatitis B virus infection is associated with decreased serum 25(OH)D concentration in non-cirrhotic patients
por: Parfieniuk-Kowerda, Anna, et al.
Publicado: (2019)

Retrospective Analysis of the Effectiveness of Remdesivir in COVID-19 Treatment during Periods Dominated by Delta and Omicron SARS-CoV-2 Variants in Clinical Settings
por: Dobrowolska, Krystyna, et al.
Publicado: (2023)

Early oral antiviral use in patients hospitalised with COVID-19
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Impact of Kidney Failure on the Severity of COVID-19
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2021)

Ways to Eliminate Viral Hepatitis as a Global Health Threat
por: Flisiak, Robert, et al.
Publicado: (2022)

Serum Cytokeratin 18 M30 Levels in Chronic Hepatitis B Reflect Both Phase and Histological Activities of Disease
por: Świderska, Magdalena, et al.
Publicado: (2017)

The association of airborne particulate matter and benzo[a]pyrene with the clinical course of COVID-19 in patients hospitalized in Poland()
por: Rzymski, Piotr, et al.
Publicado: (2022)

Change in the Clinical Picture of Hospitalized Patients with COVID-19 between the Early and Late Period of Dominance of the Omicron SARS-CoV-2 Variant
por: Flisiak, Robert, et al.
Publicado: (2023)

Effect of COVID-19 on Anti-S Antibody Response in Healthcare Workers Six Months Post-Vaccination
por: Flisiak, Robert, et al.
Publicado: (2021)

Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance
por: Flisiak, Robert, et al.
Publicado: (2022)

Correction: Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance
por: Flisiak, Robert, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k17m2vbafvm4u56k1fgkaapji7